Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Effectiveness and safety of seasonal influenza vaccination in children with underlying respiratory diseases and allergy

  • Kang, Jin-Han (Department of Pediatrics, Seoul St. Mary's Hospital, Vaccine Bio Research Institute, The Catholic University of Korea College of Medicine)
  • 투고 : 2013.12.30
  • 심사 : 2014.02.22
  • 발행 : 2014.04.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Influenza causes acute respiratory infections and various complications. Children in the high-risk group have higher complication and hospitalization rates than high-risk elderly individuals. Influenza prevention in children is important, as they can be a source infection spread in their communities. Influenza vaccination is strongly recommended for high-risk children with chronic underlying circulatory and respiratory disease, immature infants, and children receiving long-term immunosuppressant treatment or aspirin. However, vaccination rates in these children are low because of concerns regarding the exacerbation of underlying diseases and vaccine efficacy. To address these concerns, many clinical studies on children with underlying respiratory diseases have been conducted since the 1970s. Most of these reported no differences in immunogenicity or adverse reactions between healthy children and those with underlying respiratory diseases and no adverse effects of the influenza vaccine on the disease course. Further to these studies, the inactivated split-virus influenza vaccine is recommended for children with underlying respiratory disease, in many countries. However, the live-attenuated influenza vaccine (LAIV) is not recommended for children younger than 5 years with asthma or recurrent wheezing. Influenza vaccination is contraindicated in patients with severe allergies to egg, chicken, or feathers, because egg-cultivated influenza vaccines may contain ovalbumin. There has been no recent report of serious adverse events after influenza vaccination in children with egg allergy. However, many experts recommend the trivalent influenza vaccine for patients with severe egg allergy, with close observation for 30 minutes after vaccination. LAIV is still not recommended for patients with asthma or egg allergy.

키워드

참고문헌

  1. Monto AS, Koopman JS, Longini IM Jr. Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981. Am J Epidemiol 1985;121:811-22. https://doi.org/10.1093/oxfordjournals.aje.a114052
  2. Ploin D, Liberas S, Thouvenot D, Fouilhoux A, Gillet Y, Denis A, et al. Influenza burden in children newborn to eleven months of age in a pediatric emergency department during the peak of an influenza epidemic. Pediatr Infect Dis J 2003;22(10 Suppl):S218-22.
  3. Forster J. Influenza in children: the German perspective. Pediatr Infect Dis J 2003;22(10 Suppl):S215-7.
  4. Glezen WP, Keitel WA, Taber LH, Piedra PA, Clover RD, Couch RB. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol 1991;133: 296-304. https://doi.org/10.1093/oxfordjournals.aje.a115874
  5. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225-31. https://doi.org/10.1056/NEJM200001273420401
  6. Longini IM Jr, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005; 161:303-6. https://doi.org/10.1093/aje/kwi053
  7. Perrotta DM, Decker M, Glezen WP. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol 1985;122:468-76. https://doi.org/10.1093/oxfordjournals.aje.a114128
  8. Glezen WP, Payne AA, Snyder DN, Downs TD. Mortality and influenza. J Infect Dis 1982;146:313-21. https://doi.org/10.1093/infdis/146.3.313
  9. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr Infect Dis J 1997;16:1065-8. https://doi.org/10.1097/00006454-199711000-00012
  10. Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982;115:736-51. https://doi.org/10.1093/oxfordjournals.aje.a113356
  11. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978;298:587-92. https://doi.org/10.1056/NEJM197803162981103
  12. Fox JP, Hall CE, Cooney MK, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 1982; 116:212-27. https://doi.org/10.1093/oxfordjournals.aje.a113407
  13. Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993;110:145-60. https://doi.org/10.1017/S0950268800050779
  14. Couch RB. Influenza: prospects for control. Ann Intern Med 2000; 133:992-8. https://doi.org/10.7326/0003-4819-133-12-200012190-00015
  15. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-8. https://doi.org/10.1016/j.virusres.2004.02.025
  16. Ruben FL. Inactivated influenza virus vaccines in children. Clin Infect Dis 2004;38:678-88. https://doi.org/10.1086/382883
  17. Dayan GH, Nguyen VH, Debbag R, Gomez R, Wood SC. Costeffectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001;19:4204-13. https://doi.org/10.1016/S0264-410X(01)00160-8
  18. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000;106:973-6. https://doi.org/10.1542/peds.106.5.973
  19. Monto AS, Davenport FM, Napier JA, Francis T Jr. Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. Bull World Health Organ 1969;41:537-42.
  20. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001;344:889-96. https://doi.org/10.1056/NEJM200103223441204
  21. Gonzalez M, Pirez MC, Ward E, Dibarboure H, Garcia A, Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 2000;83:488-91. https://doi.org/10.1136/adc.83.6.488
  22. Centers for Disease Control (CDC). Influenza vaccine 1981-82. MMWR Morb Mortal Wkly Rep 1981;30:279-82, 287-8.
  23. Centers for Disease Control (CDC). Prevention and control of influenza. MMWR Morb Mortal Wkly Rep 1984;33:253-60, 265-6.
  24. Crawford NW, Bines JE, Royle J, Buttery JP. Optimizing immunization in pediatric special risk groups. Expert Rev Vaccines 2011;10: 175-86. https://doi.org/10.1586/erv.10.157
  25. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-64. https://doi.org/10.1056/NEJMoa0708630
  26. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9. https://doi.org/10.1056/NEJM200001273420402
  27. Kondo S, Abe K. The effects of influenza virus infection on FEV1 in asthmatic children. The time-course study. Chest 1991;100:1235-8. https://doi.org/10.1378/chest.100.5.1235
  28. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000;137:856-64. https://doi.org/10.1067/mpd.2000.110445
  29. Fairchok MP, Trementozzi DP, Carter PS, Regnery HL, Carter ER. Effect of prednisone on response to influenza virus vaccine in asthmatic children. Arch Pediatr Adolesc Med 1998;152:1191-5.
  30. Park CL, Frank AL, Sullivan M, Jindal P, Baxter BD. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 1996;98(2 Pt 1):196-200.
  31. Bell TD, Chai H, Berlow B, Daniels G. Immunization with killed influenza virus in children with chronic asthma. Chest 1978;73: 140-5. https://doi.org/10.1378/chest.73.2.140
  32. Gross PA, Ennis FA, Noble GR, Gaerlan PF, Davis WJ, Denning CE. Influenza vaccine in unprimed children: improved immunogenicity with few reactions following one high dose of split-product vaccine. J Pediatr 1980;97:56-60.
  33. Gross PA, Ennis FA, Gaerlan PF, Denning CR, Setia U, Davis WJ, et al. Comparison of new triton X-100- and tween-ether-treated splittreated vaccines in children. J Clin Microbiol 1981;14:534-8.
  34. Ghirga G, Ghirga P, Rodino P, Presti A. Safety of the subunit influenza vaccine in asthmatic children. Vaccine 1991;9:913-4.
  35. Groothuis JR, Levin MJ, Rabalais GP, Meiklejohn G, Lauer BA. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics 1991;87:823-8.
  36. Brydak LB, Fracka B, Marusak M, Rudnicka H, Nachman SA. Influenza immunization for children with bronchopulmonary dysplasia in Poland. Pediatr Infect Dis J 1997;16:538-9. https://doi.org/10.1097/00006454-199705000-00028
  37. Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA 1994; 272:1122-6. https://doi.org/10.1001/jama.1994.03520140052037
  38. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001;345:1529-36. https://doi.org/10.1056/NEJMoa011961
  39. Bueving HJ, Bernsen RM, de Jongste JC, van Suijlekom-Smit LW, Rimmelzwaan GF, Osterhaus AD, et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 2004;169:488-93. https://doi.org/10.1164/rccm.200309-1251OC
  40. Hanania NA, Sockrider M, Castro M, Holbrook JT, Tonascia J, Wise R, et al. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol 2004;113:717-24. https://doi.org/10.1016/j.jaci.2003.12.584
  41. Pedroza A, Huerta JG, Garcia Mde L, Rojas A, Lopez-Martinez I, Penagos M, et al. The safety and immunogenicity of influenza vaccine in children with asthma in Mexico. Int J Infect Dis 2009; 13:469-75. https://doi.org/10.1016/j.ijid.2008.08.015
  42. Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002;20:1240-7. https://doi.org/10.1016/S0264-410X(01)00428-5
  43. Gross PA, Gould AL, Brown AE. Effect of cancer chemotherapy on the immune response to influenza virus vaccine: review of published studies. Rev Infect Dis 1985;7:613-8. https://doi.org/10.1093/clinids/7.5.613
  44. Bae EY, Choi UY, Kwon HJ, Jeong DC, Rhim JW, Ma SH, et al. Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing. Clin Vaccine Immunol 2013;20:811-7. https://doi.org/10.1128/CVI.00008-13
  45. Miyazaki C, Nakayama M, Tanaka Y, Kusuhara K, Okada K, Tokugawa K, et al. Immunization of institutionalized asthmatic children and patients with psychomotor retardation using live attenuated coldadapted reassortment influenza A H1N1, H3N2 and B vaccines. Vaccine 1993;11:853-8. https://doi.org/10.1016/0264-410X(93)90361-Z
  46. Tanaka Y, Ueda K, Miyazaki C, Nakayama M, Kusuhara K, Okada K, et al. Trivalent cold recombinant influenza live vaccine in institutionalized children with bronchial asthma and patients with psychomotor retardation. Pediatr Infect Dis J 1993;12:600-5. https://doi.org/10.1097/00006454-199307000-00011
  47. Redding G, Walker RE, Hessel C, Virant FS, Ayars GH, Bensch G, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002; 21:44-8. https://doi.org/10.1097/00006454-200201000-00010
  48. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006;25:860-9. https://doi.org/10.1097/01.inf.0000237797.14283.cf
  49. Kelso JM. Safety of influenza vaccines. Curr Opin Allergy Clin Immunol 2012;12:383-8. https://doi.org/10.1097/ACI.0b013e328354395d
  50. Miller JR, Meltzer EO. The use of egg-containing vaccines in eggsensitive patients [abstract]. J Allergy Clin Immunol 1972;49:109.
  51. Davies R, Pepys J. Egg allergy, influenza vaccine, and immunoglobulin E antibody. J Allergy Clin Immunol 1976;57:373-83. https://doi.org/10.1016/0091-6749(76)90095-6
  52. Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP. Safety of influenza vaccination in allergic children. J Infect Dis 1977;136 Suppl:S652-5. https://doi.org/10.1093/infdis/136.Supplement_3.S652
  53. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59(RR-8):1-62.
  54. James JM, Zeiger RS, Lester MR, Fasano MB, Gern JE, Mansfield LE, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998;133:624-8. https://doi.org/10.1016/S0022-3476(98)70101-5
  55. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010;125:e1024-30. https://doi.org/10.1542/peds.2009-2512
  56. Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, et al. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2010;126:317-23. https://doi.org/10.1016/j.jaci.2010.05.037
  57. Greenhawt MJ, Chernin AS, Howe L, Li JT, Sanders G. The safety of the H1N1 influenza A vaccine in egg allergic individuals. Ann Allergy Asthma Immunol 2010;105:387-93. https://doi.org/10.1016/j.anai.2010.08.015
  58. Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol 2011;127:264-5. https://doi.org/10.1016/j.jaci.2010.10.005
  59. Webb L, Petersen M, Boden S, LaBelle V, Bird JA, Howell D, et al. Single-dose influenza vaccination of patients with egg allergy in a multicenter study. J Allergy Clin Immunol 2011;128:218-9. https://doi.org/10.1016/j.jaci.2011.02.013
  60. Howe LE, Conlon AS, Greenhawt MJ, Sanders GM. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. Ann Allergy Asthma Immunol 2011;106:446-7. https://doi.org/10.1016/j.anai.2011.01.024
  61. Li JT, Rank MA, Squillace DL, Kita H. Ovalbumin content of influenza vaccines. J Allergy Clin Immunol 2010;125:1412-3.
  62. McKinney KK, Webb L, Petersen M, Nelson M, Laubach S. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011;127:1629-32. https://doi.org/10.1016/j.jaci.2011.02.003
  63. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics 2011;128:813-25. https://doi.org/10.1542/peds.2011-2295
  64. Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. MMWR Recomm Rep 2013;62(RR-07):1-43.

피인용 문헌

  1. Safety of influenza vaccination in children with allergic diseases vol.4, pp.2, 2014, https://doi.org/10.7774/cevr.2015.4.2.137
  2. Safety of inactivated influenza vaccine against Japanese children with hen's egg allergy vol.29, pp.5, 2014, https://doi.org/10.3388/jspaci.29.665
  3. Influenza burden, prevention, and treatment in asthma‐A scoping review by the EAACI Influenza in asthma task force vol.73, pp.6, 2018, https://doi.org/10.1111/all.13333
  4. Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives vol.76, pp.6, 2014, https://doi.org/10.1111/all.14840